glp 1 uti risk GLP-1 receptor agonists' impact on cardio-renal outcomes and mortality in T2D with acute kidney disease Does GLP-1 Make You Pee

Individual results vary based on condition being treated, overall health, and treatment adherence

Opinions, joining A+B and comparing with C have very little value

"As a convenient once-daily pill, orforglipron may provide a new option and, if approved, could be readily manufactured and launched at scale for use by people around the world." In the first Phase 3 trial of the ACHIEVE program, orforglipron met the primary endpoint of superior A1C reduction compared to placebo at 40 weeks, lowering A1C by an average of 1.3% to 1.6% from a baseline of 8.0%, using the efficacy estimand

economic expansion by boosting labor productivity, decreasing obesity-related healthcare costs, and driving a massive multi-billion-dollar biopharmaceutical and consumer market

Qsymia has no direct glucose-lowering mechanism